Effective discovery of synergistic combinations by in silico prioritization
uccessful cancer therapies are often based on drug combinations to halt cancer growth and prevent resistance mechanisms. A good way to find novel, unexpected synergistic drug combinations is unbiased high throughput screening on cancer cell lines, such as the NTRC SynergyScreen™ platform.
Read more
BioConnection further strengthens its position in the (bio) pharmaceutical CMO business by adding a Flexible GMP area to its current capabilities.
BioConnection opens this month, after an intensive engineering and validation program its Flexible GMP area. The area consists of several...
Read more
CEO Monique van Scherpenzeel – “I love to get my hands dirty in the lab”
Monique van Scherpenzeel (1981) exchanged the University for the Business world. In April 2018 she started her own company, GlycoMScan,...
Read more
A cup of coffee with…. Inez de Greef (3D-PharmXchange)
Inez de Greef, co-owner and founder of 3D-PharmXchange, started the company together with Ronald van der Geest because they find the development of medicines a fascinating field of expertise. “And not only do we find the field interesting, we also find it just as motivating to be able to share our knowledge with our team and apply it to customers.”
Read more
PharmSupport starts SME GxP expertise center
The Life Sciences & Health sector is characterized by complex and demanding quality legislation and regulations (GxP, collective name for,...
Read more
Tissue-type analysis included in Oncolines™ cancer cell line profiling
The approval label of many drugs specifically states use in cancer of a certain tissue type, for instance, breast or lung. In any approach to precision medicine, cancer lineage should therefore be taken into account. NTRC’s Oncolines™ cancer cell line profiling service1,2 now includes such tissue-type analysis, indicating whether drugs or drug candidates show preferential activity in a certain cancer tissue type.
Read more
Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
Aduro Biotech announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel...
Read more
André van de Sande ambassador and advisor to Pivot Park
André van de Sande has recently been appointed as ambassador and advisor to the Pivot Park in Oss. Together with...
Read more
Foundation laid for new Q fever vaccine
Three years of research at, among others, Innatoss Laboratories in Oss laid the foundation for a new Q fever vaccine....
Read more